Analyses of vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens
Authors:
- Se SilkSSSe Silk
- Mimi M HouMHMimi M Hou
Preprint
Abstract
We have previously reported primary endpoints of a clinical trial testing two vaccine platforms for delivery of Plasmodium vivax malaria DBPRII: viral vectors (ChAd63, MVA) and protein/adjuvant (PvDBPII with 50µg Matrix-M™ adjuvant). Delayed boosting was necessitated due to trial halts during the pandemic and provides an opportunity to investigate the impact of dosing regimens. Here, using flow cytometry – including agnostic definition of B cell populations with the clustering tool CITRUS – we report enhanced induction of DBPRII-specific plasma cell and memory B cell responses in protein/adjuvant versus viral vector vaccinees. Within protein/adjuvant groups, delayed boosting further improved B cell immunogenicity as compared to a monthly boosting regimen. Consistent with this, delayed boosting also drove more durable anti-DBPRII serum IgG. In an independent vaccine clinical trial with the P. falciparum malaria RH5.1 protein/adjuvant (50µg Matrix-M™) vaccine candidate, we similarly observed enhanced circulating B cell responses in vaccinees receiving a delayed final booster. Notably, a higher frequency of vaccine-specific (putatively long-lived) plasma cells were detected in the bone marrow of these delayed boosting vaccinees by ELISPOT and correlated strongly with serum IgG. Finally, following controlled human malaria infection with P. vivax parasites in the DBPRII trial, in vivo growth inhibition was observed to correlate with DBPRII-specific B cell and serum IgG responses. In contrast, the CD4+ and CD8+ T cell responses were impacted by vaccine platform but not dosing regimen, and did not correlate with in vivo growth inhibition in a challenge model. Taken together, our DBPRII and RH5 data suggest an opportunity for dosing regimen optimisation in the context of rational vaccine development against pathogens where protection is antibody-mediated.Keywords
All Related Versions
- Published version: Frontiers in Immunology, 14, 1193079.
This publication has 23 references indexed in Scilit:
- Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma CellsFrontiers in Immunology, 2019
- SIMON, an Automated Machine Learning System, Reveals Immune Signatures of Influenza Vaccine ResponsesThe Journal of Immunology, 2019
- Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosisScientific Reports, 2017
- Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell TransitionThe Journal of Immunology, 2017
- Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity StudyThe Journal of Infectious Diseases, 2016
- Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone MarrowImmunity, 2015
- A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrowBlood, 2015
- Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria InfectionThe Journal of Infectious Diseases, 2013
- Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccinesVaccine, 2008
- A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalariaNew England Journal of Medicine, 1997